[HTML][HTML] 恩沙替尼治疗EML4-ALK/TP53 共突变肺鳞癌1 例并文献复习
LV Donglai, XU Chunwei, W Chong… - … Journal of Lung Cancer, 2023 - ncbi.nlm.nih.gov
… patients treated with targeted therapy since literature … EML4-ALK and TP53 positive LSCC,
and the relevant literatures were reviewed for discussing the treatment of this rare disease…
and the relevant literatures were reviewed for discussing the treatment of this rare disease…
[HTML][HTML] 伴有CLIP1-ALK 融合基因晚期肺鳞癌1 例
袁月， 王征， 聂鑫， 张萍， 李琳 - Chinese Journal of Lung Cancer, 2022 - ncbi.nlm.nih.gov
… Lewis等 [9] 回顾了6例具有EML4-ALK重排的肺鳞癌患者的治疗过程，使用ALK抑制剂作为
一线或二线治疗的中位PFS为2.8（1.8-6.3）个月，OS为8.3（3.2-32.1）个月。本文中患者OS与既往…
一线或二线治疗的中位PFS为2.8（1.8-6.3）个月，OS为8.3（3.2-32.1）个月。本文中患者OS与既往…
[HTML][HTML] 腺鳞癌转化在肺癌耐药中的功能和机制研究
陈玥清， 陈雨婷， 童欣媛， 季红斌 - 生物医学转化, 2021 - swyxzh.ijournals.cn
… in a patient with EML4-ALK fusion variant 5 refractory to ALK … Thyroid carcinoma with
papillary and squamous features:… failed from chemotherapy, targeted therapy or immunotherapy. …
papillary and squamous features:… failed from chemotherapy, targeted therapy or immunotherapy. …
[HTML][HTML] 分子靶向治疗在肺鳞癌中的研究进展
马丽， 张树才 - Chinese Journal of Lung Cancer, 2013 - ncbi.nlm.nih.gov
… targeted genes in the genome of squamous-cell lung cancer … p63和甲状腺转录因子-1（thyroid
transcription factor-1, TTF-1）… 下，如KRAS、BRAF、EGFR和EML4-ALK的基因变异。部分靶点…
transcription factor-1, TTF-1）… 下，如KRAS、BRAF、EGFR和EML4-ALK的基因变异。部分靶点…
[PDF][PDF] 甲状腺癌诊断及预后相关分子标志物的研究进展
梅志丹， 陈晨， 胡章威， 郑安元， 陶泽璋 - 现代生物医学进展, 2017 - biomed.cnjournals.com
… A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma[J]. …
-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target [J]. …
-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target [J]. …
[HTML][HTML] 肺微乳头腺癌病理学及分子学特征研究进展
梁佳凤， 吴琼， 马胜林， 张仕蓉 - Chinese Journal of Lung Cancer, 2020 - ncbi.nlm.nih.gov
… Specific genetic variation The percentage of variated patients in LMPC patients The
percentage of related variated patients in their lung cancer subtypes Whether variation correlated …
percentage of related variated patients in their lung cancer subtypes Whether variation correlated …
[HTML][HTML] 驱动基因阳性且PD-L1 高表达的非小细胞肺癌患者病理特征及靶向治疗疗效评估的真实世界研究
张卉， 杨新杰， 李琨， 王敬慧， 吕嘉林… - … of Lung Cancer, 2021 - ncbi.nlm.nih.gov
… in detail for targeted therapy, who with ALK fusion-positive and PD-… EML4-ALK融合阳性
，PD-L1表达量90%。治疗一线给予克唑替尼单药治疗，1个月后CT评估疗效病情稳定（stable disease…
，PD-L1表达量90%。治疗一线给予克唑替尼单药治疗，1个月后CT评估疗效病情稳定（stable disease…
外泌体在肿瘤精准诊疗中的应用前景与挑战
李冬阳， 刘云鹏， 车晓芳 - 肿瘤综合治疗电子杂志, 2022 - jmcm2018.com
… 于检测非小细胞肺癌患者的EML4-ALK 突变,也获得了美国食品药品… Urinary exosomal
thyroglobulin in thyroid cancer patients … for targeted glioma therapy[J]. Biomater, 2021, …
thyroglobulin in thyroid cancer patients … for targeted glioma therapy[J]. Biomater, 2021, …